GlassScriptPhysician profile
Elizabeth Lokenauth
NPI 1487321790
$6,763.10
in general payments reported to CMS, 2019-2025
21 companies · $2,105 in 2025
The $2,105 reported for 2025 was more than what 93% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $705 · 2023: $1,875 · 2024: $2,079 · 2025: $2,105.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,965 · Education: $93.94.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,964.60 |
| Education | $93.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,106.28 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $749.54 | 2023-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $736.83 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $608.12 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $456.24 | 2022-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $333.72 | 2023-2025 | Auvelity |
| Alkermes, INC. | $307.81 | 2022-2025 | Lybalvi, Aristada |
| Lundbeck LLC | $256.45 | 2022-2025 | Rexulti, Abilify Maintena |
| Vanda Pharmaceuticals INC. | $234.15 | 2023-2025 | Fanapt, Hetlioz |
| Ironshore Pharmaceuticals INC. | $198.17 | 2022-2024 | Jornay Pm |
| E.R. Squibb & Sons, L.L.C. | $157.46 | 2024-2025 | Cobenfy |
| Almatica Pharma LLC | $101.77 | 2023-2024 | Loreev Xr, Gralise |
| Tris Pharma INC | $94.82 | 2024-2025 | Onyda Xr, Dyanavel Xr |
| Supernus Pharmaceuticals, INC. | $88.84 | 2024-2025 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $76.14 | 2022-2024 | Trintellix |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $71.06 | 2023-2024 | Azstarys |
| Bausch Health US, LLC | $70.55 | 2023-2025 | Aplenzin, Wellbutrin |
| Teva Pharmaceuticals USA, INC. | $44.40 | 2023-2024 | Austedo Xr, Uzedy |
| Indivior INC. | $42.37 | 2023 | Perseris |
| Idorsia Pharmaceuticals US INC | $15.24 | 2023 | Quviviq |
| Neos Therapeutics, LP | $13.14 | 2023 | Adzenys Xr-Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Lokenauth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.